Application | Comment | Organism |
---|---|---|
medicine | octapeptide inhibitor LSCQLYQR and derivatives are expected to work in combination with more aggressive chemotherapeutic agents in cancer cells to improve the efficacy, fight platinum-induced drug resistance, and reduce the overall drug combination toxicities. The cellular half-life observed for the peptide suggests that more chemical changes should be performed for an acceptable in vivo pharmacokinetics | Homo sapiens |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
LSCQLYQR | octapeptide to specifically target the monomer-monomer interface of the enzyme. A fast-equilibrium mechanism exists that combines trafficking in/out of the cell and degradation pathways within cells | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | - |
- |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
ovary cancer cell line | epithelial ovarian cancer cell line resistant to cisplatin | Homo sapiens | - |